Influenzavirus B Infection Drug Market, Global Outlook and Forecast 2022-2028
This report contains market size and forecasts of Influenzavirus B Infection Drug in global, including the following market information:
Global Influenzavirus B Infection Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Influenzavirus B Infection Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Influenzavirus B Infection Drug companies in 2021 (%)
The global Influenzavirus B Infection Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
APP-309 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Influenzavirus B Infection Drug include AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp, BioCryst Pharmaceuticals Inc, Cadila Healthcare Ltd, ContraFect Corp and Daiichi Sankyo Company Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Influenzavirus B Infection Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Influenzavirus B Infection Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Influenzavirus B Infection Drug Market Segment Percentages, by Type, 2021 (%)
Global Influenzavirus B Infection Drug Market Segment Percentages, by Application, 2021 (%)
Global Influenzavirus B Infection Drug Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Influenzavirus B Infection Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Influenzavirus B Infection Drug revenues share in global market, 2021 (%)
Key companies Influenzavirus B Infection Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Influenzavirus B Infection Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Global Influenzavirus B Infection Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Influenzavirus B Infection Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Influenzavirus B Infection Drug companies in 2021 (%)
The global Influenzavirus B Infection Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
APP-309 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Influenzavirus B Infection Drug include AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp, BioCryst Pharmaceuticals Inc, Cadila Healthcare Ltd, ContraFect Corp and Daiichi Sankyo Company Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Influenzavirus B Infection Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Influenzavirus B Infection Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Influenzavirus B Infection Drug Market Segment Percentages, by Type, 2021 (%)
- APP-309
- CF-403
- GC-3106A
- KIN-1400
- Others
Global Influenzavirus B Infection Drug Market Segment Percentages, by Application, 2021 (%)
- Clinic
- Hospital
- Others
Global Influenzavirus B Infection Drug Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Influenzavirus B Infection Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Influenzavirus B Infection Drug revenues share in global market, 2021 (%)
Key companies Influenzavirus B Infection Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Influenzavirus B Infection Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AbbVie Inc
- Adimmune Corp
- Altravax Inc
- Amarillo Biosciences Inc
- Aphios Corp
- BioCryst Pharmaceuticals Inc
- Cadila Healthcare Ltd
- ContraFect Corp
- Daiichi Sankyo Company Ltd
- Fujifilm Holdings Corporation
- GlaxoSmithKline Plc
- Green Cross Corp
- Inovio Pharmaceuticals Inc
- Kineta Inc
- Medicago Inc
- MedImmune LLC
- Mucosis BV
- Novavax Inc
- Park Active Molecules
- Romark Laboratories LC
- Sanofi
- Sanofi Pasteur SA
- Shionogi & Co Ltd
- SK Chemicals Co Ltd
- TSRL Inc
- Vaxart Inc
- Vectura Group Plc
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Influenzavirus B Infection Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Influenzavirus B Infection Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL INFLUENZAVIRUS B INFECTION DRUG OVERALL MARKET SIZE
2.1 Global Influenzavirus B Infection Drug Market Size: 2021 VS 2028
2.2 Global Influenzavirus B Infection Drug Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Influenzavirus B Infection Drug Sales: 2017-2028
3 COMPANY LANDSCAPE
3.1 Top Influenzavirus B Infection Drug Players in Global Market
3.2 Top Global Influenzavirus B Infection Drug Companies Ranked by Revenue
3.3 Global Influenzavirus B Infection Drug Revenue by Companies
3.4 Global Influenzavirus B Infection Drug Sales by Companies
3.5 Global Influenzavirus B Infection Drug Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Influenzavirus B Infection Drug Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Influenzavirus B Infection Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Influenzavirus B Infection Drug Players in Global Market
3.8.1 List of Global Tier 1 Influenzavirus B Infection Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Influenzavirus B Infection Drug Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Influenzavirus B Infection Drug Market Size Markets, 2021 & 2028
4.1.2 APP-309
4.1.3 CF-403
4.1.4 GC-3106A
4.1.5 KIN-1400
4.1.6 Others
4.2 By Type - Global Influenzavirus B Infection Drug Revenue & Forecasts
4.2.1 By Type - Global Influenzavirus B Infection Drug Revenue, 2017-2022
4.2.2 By Type - Global Influenzavirus B Infection Drug Revenue, 2023-2028
4.2.3 By Type - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
4.3 By Type - Global Influenzavirus B Infection Drug Sales & Forecasts
4.3.1 By Type - Global Influenzavirus B Infection Drug Sales, 2017-2022
4.3.2 By Type - Global Influenzavirus B Infection Drug Sales, 2023-2028
4.3.3 By Type - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
4.4 By Type - Global Influenzavirus B Infection Drug Price (Manufacturers Selling Prices), 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Influenzavirus B Infection Drug Market Size, 2021 & 2028
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Influenzavirus B Infection Drug Revenue & Forecasts
5.2.1 By Application - Global Influenzavirus B Infection Drug Revenue, 2017-2022
5.2.2 By Application - Global Influenzavirus B Infection Drug Revenue, 2023-2028
5.2.3 By Application - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
5.3 By Application - Global Influenzavirus B Infection Drug Sales & Forecasts
5.3.1 By Application - Global Influenzavirus B Infection Drug Sales, 2017-2022
5.3.2 By Application - Global Influenzavirus B Infection Drug Sales, 2023-2028
5.3.3 By Application - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
5.4 By Application - Global Influenzavirus B Infection Drug Price (Manufacturers Selling Prices), 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Influenzavirus B Infection Drug Market Size, 2021 & 2028
6.2 By Region - Global Influenzavirus B Infection Drug Revenue & Forecasts
6.2.1 By Region - Global Influenzavirus B Infection Drug Revenue, 2017-2022
6.2.2 By Region - Global Influenzavirus B Infection Drug Revenue, 2023-2028
6.2.3 By Region - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
6.3 By Region - Global Influenzavirus B Infection Drug Sales & Forecasts
6.3.1 By Region - Global Influenzavirus B Infection Drug Sales, 2017-2022
6.3.2 By Region - Global Influenzavirus B Infection Drug Sales, 2023-2028
6.3.3 By Region - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Influenzavirus B Infection Drug Revenue, 2017-2028
6.4.2 By Country - North America Influenzavirus B Infection Drug Sales, 2017-2028
6.4.3 US Influenzavirus B Infection Drug Market Size, 2017-2028
6.4.4 Canada Influenzavirus B Infection Drug Market Size, 2017-2028
6.4.5 Mexico Influenzavirus B Infection Drug Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Influenzavirus B Infection Drug Revenue, 2017-2028
6.5.2 By Country - Europe Influenzavirus B Infection Drug Sales, 2017-2028
6.5.3 Germany Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.4 France Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.5 U.K. Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.6 Italy Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.7 Russia Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.8 Nordic Countries Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.9 Benelux Influenzavirus B Infection Drug Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Influenzavirus B Infection Drug Revenue, 2017-2028
6.6.2 By Region - Asia Influenzavirus B Infection Drug Sales, 2017-2028
6.6.3 China Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.4 Japan Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.5 South Korea Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.6 Southeast Asia Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.7 India Influenzavirus B Infection Drug Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Influenzavirus B Infection Drug Revenue, 2017-2028
6.7.2 By Country - South America Influenzavirus B Infection Drug Sales, 2017-2028
6.7.3 Brazil Influenzavirus B Infection Drug Market Size, 2017-2028
6.7.4 Argentina Influenzavirus B Infection Drug Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, 2017-2028
6.8.3 Turkey Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.4 Israel Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.5 Saudi Arabia Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.6 UAE Influenzavirus B Infection Drug Market Size, 2017-2028
7 MANUFACTURERS & BRANDS PROFILES
7.1 AbbVie Inc
7.1.1 AbbVie Inc Corporate Summary
7.1.2 AbbVie Inc Business Overview
7.1.3 AbbVie Inc Influenzavirus B Infection Drug Major Product Offerings
7.1.4 AbbVie Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.1.5 AbbVie Inc Key News
7.2 Adimmune Corp
7.2.1 Adimmune Corp Corporate Summary
7.2.2 Adimmune Corp Business Overview
7.2.3 Adimmune Corp Influenzavirus B Infection Drug Major Product Offerings
7.2.4 Adimmune Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.2.5 Adimmune Corp Key News
7.3 Altravax Inc
7.3.1 Altravax Inc Corporate Summary
7.3.2 Altravax Inc Business Overview
7.3.3 Altravax Inc Influenzavirus B Infection Drug Major Product Offerings
7.3.4 Altravax Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.3.5 Altravax Inc Key News
7.4 Amarillo Biosciences Inc
7.4.1 Amarillo Biosciences Inc Corporate Summary
7.4.2 Amarillo Biosciences Inc Business Overview
7.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Major Product Offerings
7.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.4.5 Amarillo Biosciences Inc Key News
7.5 Aphios Corp
7.5.1 Aphios Corp Corporate Summary
7.5.2 Aphios Corp Business Overview
7.5.3 Aphios Corp Influenzavirus B Infection Drug Major Product Offerings
7.5.4 Aphios Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.5.5 Aphios Corp Key News
7.6 BioCryst Pharmaceuticals Inc
7.6.1 BioCryst Pharmaceuticals Inc Corporate Summary
7.6.2 BioCryst Pharmaceuticals Inc Business Overview
7.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Major Product Offerings
7.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.6.5 BioCryst Pharmaceuticals Inc Key News
7.7 Cadila Healthcare Ltd
7.7.1 Cadila Healthcare Ltd Corporate Summary
7.7.2 Cadila Healthcare Ltd Business Overview
7.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Major Product Offerings
7.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.7.5 Cadila Healthcare Ltd Key News
7.8 ContraFect Corp
7.8.1 ContraFect Corp Corporate Summary
7.8.2 ContraFect Corp Business Overview
7.8.3 ContraFect Corp Influenzavirus B Infection Drug Major Product Offerings
7.8.4 ContraFect Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.8.5 ContraFect Corp Key News
7.9 Daiichi Sankyo Company Ltd
7.9.1 Daiichi Sankyo Company Ltd Corporate Summary
7.9.2 Daiichi Sankyo Company Ltd Business Overview
7.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Major Product Offerings
7.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.9.5 Daiichi Sankyo Company Ltd Key News
7.10 Fujifilm Holdings Corporation
7.10.1 Fujifilm Holdings Corporation Corporate Summary
7.10.2 Fujifilm Holdings Corporation Business Overview
7.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Major Product Offerings
7.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.10.5 Fujifilm Holdings Corporation Key News
7.11 GlaxoSmithKline Plc
7.11.1 GlaxoSmithKline Plc Corporate Summary
7.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Business Overview
7.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Major Product Offerings
7.11.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.11.5 GlaxoSmithKline Plc Key News
7.12 Green Cross Corp
7.12.1 Green Cross Corp Corporate Summary
7.12.2 Green Cross Corp Influenzavirus B Infection Drug Business Overview
7.12.3 Green Cross Corp Influenzavirus B Infection Drug Major Product Offerings
7.12.4 Green Cross Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.12.5 Green Cross Corp Key News
7.13 Inovio Pharmaceuticals Inc
7.13.1 Inovio Pharmaceuticals Inc Corporate Summary
7.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Business Overview
7.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Major Product Offerings
7.13.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.13.5 Inovio Pharmaceuticals Inc Key News
7.14 Kineta Inc
7.14.1 Kineta Inc Corporate Summary
7.14.2 Kineta Inc Business Overview
7.14.3 Kineta Inc Influenzavirus B Infection Drug Major Product Offerings
7.14.4 Kineta Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.14.5 Kineta Inc Key News
7.15 Medicago Inc
7.15.1 Medicago Inc Corporate Summary
7.15.2 Medicago Inc Business Overview
7.15.3 Medicago Inc Influenzavirus B Infection Drug Major Product Offerings
7.15.4 Medicago Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.15.5 Medicago Inc Key News
7.16 MedImmune LLC
7.16.1 MedImmune LLC Corporate Summary
7.16.2 MedImmune LLC Business Overview
7.16.3 MedImmune LLC Influenzavirus B Infection Drug Major Product Offerings
7.16.4 MedImmune LLC Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.16.5 MedImmune LLC Key News
7.17 Mucosis BV
7.17.1 Mucosis BV Corporate Summary
7.17.2 Mucosis BV Business Overview
7.17.3 Mucosis BV Influenzavirus B Infection Drug Major Product Offerings
7.17.4 Mucosis BV Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.17.5 Mucosis BV Key News
7.18 Novavax Inc
7.18.1 Novavax Inc Corporate Summary
7.18.2 Novavax Inc Business Overview
7.18.3 Novavax Inc Influenzavirus B Infection Drug Major Product Offerings
7.18.4 Novavax Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.18.5 Novavax Inc Key News
7.19 Park Active Molecules
7.19.1 Park Active Molecules Corporate Summary
7.19.2 Park Active Molecules Business Overview
7.19.3 Park Active Molecules Influenzavirus B Infection Drug Major Product Offerings
7.19.4 Park Active Molecules Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.19.5 Park Active Molecules Key News
7.20 Romark Laboratories LC
7.20.1 Romark Laboratories LC Corporate Summary
7.20.2 Romark Laboratories LC Business Overview
7.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Major Product Offerings
7.20.4 Romark Laboratories LC Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.20.5 Romark Laboratories LC Key News
7.21 Sanofi
7.21.1 Sanofi Corporate Summary
7.21.2 Sanofi Business Overview
7.21.3 Sanofi Influenzavirus B Infection Drug Major Product Offerings
7.21.4 Sanofi Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.21.5 Sanofi Key News
7.22 Sanofi Pasteur SA
7.22.1 Sanofi Pasteur SA Corporate Summary
7.22.2 Sanofi Pasteur SA Business Overview
7.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Major Product Offerings
7.22.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.22.5 Sanofi Pasteur SA Key News
7.23 Shionogi & Co Ltd
7.23.1 Shionogi & Co Ltd Corporate Summary
7.23.2 Shionogi & Co Ltd Business Overview
7.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Major Product Offerings
7.23.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.23.5 Shionogi & Co Ltd Key News
7.24 SK Chemicals Co Ltd
7.24.1 SK Chemicals Co Ltd Corporate Summary
7.24.2 SK Chemicals Co Ltd Business Overview
7.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Major Product Offerings
7.24.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.24.5 SK Chemicals Co Ltd Key News
7.25 TSRL Inc
7.25.1 TSRL Inc Corporate Summary
7.25.2 TSRL Inc Business Overview
7.25.3 TSRL Inc Influenzavirus B Infection Drug Major Product Offerings
7.25.4 TSRL Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.25.5 TSRL Inc Key News
7.26 Vaxart Inc
7.26.1 Vaxart Inc Corporate Summary
7.26.2 Vaxart Inc Business Overview
7.26.3 Vaxart Inc Influenzavirus B Infection Drug Major Product Offerings
7.26.4 Vaxart Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.26.5 Vaxart Inc Key News
7.27 Vectura Group Plc
7.27.1 Vectura Group Plc Corporate Summary
7.27.2 Vectura Group Plc Business Overview
7.27.3 Vectura Group Plc Influenzavirus B Infection Drug Major Product Offerings
7.27.4 Vectura Group Plc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.27.5 Vectura Group Plc Key News
8 GLOBAL INFLUENZAVIRUS B INFECTION DRUG PRODUCTION CAPACITY, ANALYSIS
8.1 Global Influenzavirus B Infection Drug Production Capacity, 2017-2028
8.2 Influenzavirus B Infection Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Influenzavirus B Infection Drug Production by Region
9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 INFLUENZAVIRUS B INFECTION DRUG SUPPLY CHAIN ANALYSIS
10.1 Influenzavirus B Infection Drug Industry Value Chain
10.2 Influenzavirus B Infection Drug Upstream Market
10.3 Influenzavirus B Infection Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Influenzavirus B Infection Drug Distributors and Sales Agents in Global
11 CONCLUSION
12 APPENDIX
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
1.1 Influenzavirus B Infection Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Influenzavirus B Infection Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL INFLUENZAVIRUS B INFECTION DRUG OVERALL MARKET SIZE
2.1 Global Influenzavirus B Infection Drug Market Size: 2021 VS 2028
2.2 Global Influenzavirus B Infection Drug Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Influenzavirus B Infection Drug Sales: 2017-2028
3 COMPANY LANDSCAPE
3.1 Top Influenzavirus B Infection Drug Players in Global Market
3.2 Top Global Influenzavirus B Infection Drug Companies Ranked by Revenue
3.3 Global Influenzavirus B Infection Drug Revenue by Companies
3.4 Global Influenzavirus B Infection Drug Sales by Companies
3.5 Global Influenzavirus B Infection Drug Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Influenzavirus B Infection Drug Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Influenzavirus B Infection Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Influenzavirus B Infection Drug Players in Global Market
3.8.1 List of Global Tier 1 Influenzavirus B Infection Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Influenzavirus B Infection Drug Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Influenzavirus B Infection Drug Market Size Markets, 2021 & 2028
4.1.2 APP-309
4.1.3 CF-403
4.1.4 GC-3106A
4.1.5 KIN-1400
4.1.6 Others
4.2 By Type - Global Influenzavirus B Infection Drug Revenue & Forecasts
4.2.1 By Type - Global Influenzavirus B Infection Drug Revenue, 2017-2022
4.2.2 By Type - Global Influenzavirus B Infection Drug Revenue, 2023-2028
4.2.3 By Type - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
4.3 By Type - Global Influenzavirus B Infection Drug Sales & Forecasts
4.3.1 By Type - Global Influenzavirus B Infection Drug Sales, 2017-2022
4.3.2 By Type - Global Influenzavirus B Infection Drug Sales, 2023-2028
4.3.3 By Type - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
4.4 By Type - Global Influenzavirus B Infection Drug Price (Manufacturers Selling Prices), 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Influenzavirus B Infection Drug Market Size, 2021 & 2028
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Influenzavirus B Infection Drug Revenue & Forecasts
5.2.1 By Application - Global Influenzavirus B Infection Drug Revenue, 2017-2022
5.2.2 By Application - Global Influenzavirus B Infection Drug Revenue, 2023-2028
5.2.3 By Application - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
5.3 By Application - Global Influenzavirus B Infection Drug Sales & Forecasts
5.3.1 By Application - Global Influenzavirus B Infection Drug Sales, 2017-2022
5.3.2 By Application - Global Influenzavirus B Infection Drug Sales, 2023-2028
5.3.3 By Application - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
5.4 By Application - Global Influenzavirus B Infection Drug Price (Manufacturers Selling Prices), 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Influenzavirus B Infection Drug Market Size, 2021 & 2028
6.2 By Region - Global Influenzavirus B Infection Drug Revenue & Forecasts
6.2.1 By Region - Global Influenzavirus B Infection Drug Revenue, 2017-2022
6.2.2 By Region - Global Influenzavirus B Infection Drug Revenue, 2023-2028
6.2.3 By Region - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
6.3 By Region - Global Influenzavirus B Infection Drug Sales & Forecasts
6.3.1 By Region - Global Influenzavirus B Infection Drug Sales, 2017-2022
6.3.2 By Region - Global Influenzavirus B Infection Drug Sales, 2023-2028
6.3.3 By Region - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Influenzavirus B Infection Drug Revenue, 2017-2028
6.4.2 By Country - North America Influenzavirus B Infection Drug Sales, 2017-2028
6.4.3 US Influenzavirus B Infection Drug Market Size, 2017-2028
6.4.4 Canada Influenzavirus B Infection Drug Market Size, 2017-2028
6.4.5 Mexico Influenzavirus B Infection Drug Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Influenzavirus B Infection Drug Revenue, 2017-2028
6.5.2 By Country - Europe Influenzavirus B Infection Drug Sales, 2017-2028
6.5.3 Germany Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.4 France Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.5 U.K. Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.6 Italy Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.7 Russia Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.8 Nordic Countries Influenzavirus B Infection Drug Market Size, 2017-2028
6.5.9 Benelux Influenzavirus B Infection Drug Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Influenzavirus B Infection Drug Revenue, 2017-2028
6.6.2 By Region - Asia Influenzavirus B Infection Drug Sales, 2017-2028
6.6.3 China Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.4 Japan Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.5 South Korea Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.6 Southeast Asia Influenzavirus B Infection Drug Market Size, 2017-2028
6.6.7 India Influenzavirus B Infection Drug Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Influenzavirus B Infection Drug Revenue, 2017-2028
6.7.2 By Country - South America Influenzavirus B Infection Drug Sales, 2017-2028
6.7.3 Brazil Influenzavirus B Infection Drug Market Size, 2017-2028
6.7.4 Argentina Influenzavirus B Infection Drug Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, 2017-2028
6.8.3 Turkey Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.4 Israel Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.5 Saudi Arabia Influenzavirus B Infection Drug Market Size, 2017-2028
6.8.6 UAE Influenzavirus B Infection Drug Market Size, 2017-2028
7 MANUFACTURERS & BRANDS PROFILES
7.1 AbbVie Inc
7.1.1 AbbVie Inc Corporate Summary
7.1.2 AbbVie Inc Business Overview
7.1.3 AbbVie Inc Influenzavirus B Infection Drug Major Product Offerings
7.1.4 AbbVie Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.1.5 AbbVie Inc Key News
7.2 Adimmune Corp
7.2.1 Adimmune Corp Corporate Summary
7.2.2 Adimmune Corp Business Overview
7.2.3 Adimmune Corp Influenzavirus B Infection Drug Major Product Offerings
7.2.4 Adimmune Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.2.5 Adimmune Corp Key News
7.3 Altravax Inc
7.3.1 Altravax Inc Corporate Summary
7.3.2 Altravax Inc Business Overview
7.3.3 Altravax Inc Influenzavirus B Infection Drug Major Product Offerings
7.3.4 Altravax Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.3.5 Altravax Inc Key News
7.4 Amarillo Biosciences Inc
7.4.1 Amarillo Biosciences Inc Corporate Summary
7.4.2 Amarillo Biosciences Inc Business Overview
7.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Major Product Offerings
7.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.4.5 Amarillo Biosciences Inc Key News
7.5 Aphios Corp
7.5.1 Aphios Corp Corporate Summary
7.5.2 Aphios Corp Business Overview
7.5.3 Aphios Corp Influenzavirus B Infection Drug Major Product Offerings
7.5.4 Aphios Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.5.5 Aphios Corp Key News
7.6 BioCryst Pharmaceuticals Inc
7.6.1 BioCryst Pharmaceuticals Inc Corporate Summary
7.6.2 BioCryst Pharmaceuticals Inc Business Overview
7.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Major Product Offerings
7.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.6.5 BioCryst Pharmaceuticals Inc Key News
7.7 Cadila Healthcare Ltd
7.7.1 Cadila Healthcare Ltd Corporate Summary
7.7.2 Cadila Healthcare Ltd Business Overview
7.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Major Product Offerings
7.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.7.5 Cadila Healthcare Ltd Key News
7.8 ContraFect Corp
7.8.1 ContraFect Corp Corporate Summary
7.8.2 ContraFect Corp Business Overview
7.8.3 ContraFect Corp Influenzavirus B Infection Drug Major Product Offerings
7.8.4 ContraFect Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.8.5 ContraFect Corp Key News
7.9 Daiichi Sankyo Company Ltd
7.9.1 Daiichi Sankyo Company Ltd Corporate Summary
7.9.2 Daiichi Sankyo Company Ltd Business Overview
7.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Major Product Offerings
7.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.9.5 Daiichi Sankyo Company Ltd Key News
7.10 Fujifilm Holdings Corporation
7.10.1 Fujifilm Holdings Corporation Corporate Summary
7.10.2 Fujifilm Holdings Corporation Business Overview
7.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Major Product Offerings
7.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.10.5 Fujifilm Holdings Corporation Key News
7.11 GlaxoSmithKline Plc
7.11.1 GlaxoSmithKline Plc Corporate Summary
7.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Business Overview
7.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Major Product Offerings
7.11.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.11.5 GlaxoSmithKline Plc Key News
7.12 Green Cross Corp
7.12.1 Green Cross Corp Corporate Summary
7.12.2 Green Cross Corp Influenzavirus B Infection Drug Business Overview
7.12.3 Green Cross Corp Influenzavirus B Infection Drug Major Product Offerings
7.12.4 Green Cross Corp Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.12.5 Green Cross Corp Key News
7.13 Inovio Pharmaceuticals Inc
7.13.1 Inovio Pharmaceuticals Inc Corporate Summary
7.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Business Overview
7.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Major Product Offerings
7.13.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.13.5 Inovio Pharmaceuticals Inc Key News
7.14 Kineta Inc
7.14.1 Kineta Inc Corporate Summary
7.14.2 Kineta Inc Business Overview
7.14.3 Kineta Inc Influenzavirus B Infection Drug Major Product Offerings
7.14.4 Kineta Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.14.5 Kineta Inc Key News
7.15 Medicago Inc
7.15.1 Medicago Inc Corporate Summary
7.15.2 Medicago Inc Business Overview
7.15.3 Medicago Inc Influenzavirus B Infection Drug Major Product Offerings
7.15.4 Medicago Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.15.5 Medicago Inc Key News
7.16 MedImmune LLC
7.16.1 MedImmune LLC Corporate Summary
7.16.2 MedImmune LLC Business Overview
7.16.3 MedImmune LLC Influenzavirus B Infection Drug Major Product Offerings
7.16.4 MedImmune LLC Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.16.5 MedImmune LLC Key News
7.17 Mucosis BV
7.17.1 Mucosis BV Corporate Summary
7.17.2 Mucosis BV Business Overview
7.17.3 Mucosis BV Influenzavirus B Infection Drug Major Product Offerings
7.17.4 Mucosis BV Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.17.5 Mucosis BV Key News
7.18 Novavax Inc
7.18.1 Novavax Inc Corporate Summary
7.18.2 Novavax Inc Business Overview
7.18.3 Novavax Inc Influenzavirus B Infection Drug Major Product Offerings
7.18.4 Novavax Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.18.5 Novavax Inc Key News
7.19 Park Active Molecules
7.19.1 Park Active Molecules Corporate Summary
7.19.2 Park Active Molecules Business Overview
7.19.3 Park Active Molecules Influenzavirus B Infection Drug Major Product Offerings
7.19.4 Park Active Molecules Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.19.5 Park Active Molecules Key News
7.20 Romark Laboratories LC
7.20.1 Romark Laboratories LC Corporate Summary
7.20.2 Romark Laboratories LC Business Overview
7.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Major Product Offerings
7.20.4 Romark Laboratories LC Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.20.5 Romark Laboratories LC Key News
7.21 Sanofi
7.21.1 Sanofi Corporate Summary
7.21.2 Sanofi Business Overview
7.21.3 Sanofi Influenzavirus B Infection Drug Major Product Offerings
7.21.4 Sanofi Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.21.5 Sanofi Key News
7.22 Sanofi Pasteur SA
7.22.1 Sanofi Pasteur SA Corporate Summary
7.22.2 Sanofi Pasteur SA Business Overview
7.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Major Product Offerings
7.22.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.22.5 Sanofi Pasteur SA Key News
7.23 Shionogi & Co Ltd
7.23.1 Shionogi & Co Ltd Corporate Summary
7.23.2 Shionogi & Co Ltd Business Overview
7.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Major Product Offerings
7.23.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.23.5 Shionogi & Co Ltd Key News
7.24 SK Chemicals Co Ltd
7.24.1 SK Chemicals Co Ltd Corporate Summary
7.24.2 SK Chemicals Co Ltd Business Overview
7.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Major Product Offerings
7.24.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.24.5 SK Chemicals Co Ltd Key News
7.25 TSRL Inc
7.25.1 TSRL Inc Corporate Summary
7.25.2 TSRL Inc Business Overview
7.25.3 TSRL Inc Influenzavirus B Infection Drug Major Product Offerings
7.25.4 TSRL Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.25.5 TSRL Inc Key News
7.26 Vaxart Inc
7.26.1 Vaxart Inc Corporate Summary
7.26.2 Vaxart Inc Business Overview
7.26.3 Vaxart Inc Influenzavirus B Infection Drug Major Product Offerings
7.26.4 Vaxart Inc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.26.5 Vaxart Inc Key News
7.27 Vectura Group Plc
7.27.1 Vectura Group Plc Corporate Summary
7.27.2 Vectura Group Plc Business Overview
7.27.3 Vectura Group Plc Influenzavirus B Infection Drug Major Product Offerings
7.27.4 Vectura Group Plc Influenzavirus B Infection Drug Sales and Revenue in Global (2017-2022)
7.27.5 Vectura Group Plc Key News
8 GLOBAL INFLUENZAVIRUS B INFECTION DRUG PRODUCTION CAPACITY, ANALYSIS
8.1 Global Influenzavirus B Infection Drug Production Capacity, 2017-2028
8.2 Influenzavirus B Infection Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Influenzavirus B Infection Drug Production by Region
9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 INFLUENZAVIRUS B INFECTION DRUG SUPPLY CHAIN ANALYSIS
10.1 Influenzavirus B Infection Drug Industry Value Chain
10.2 Influenzavirus B Infection Drug Upstream Market
10.3 Influenzavirus B Infection Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Influenzavirus B Infection Drug Distributors and Sales Agents in Global
11 CONCLUSION
12 APPENDIX
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES
Table 1. Key Players of Influenzavirus B Infection Drug in Global Market
Table 2. Top Influenzavirus B Infection Drug Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Influenzavirus B Infection Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Influenzavirus B Infection Drug Revenue Share by Companies, 2017-2022
Table 5. Global Influenzavirus B Infection Drug Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Influenzavirus B Infection Drug Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Influenzavirus B Infection Drug Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Influenzavirus B Infection Drug Product Type
Table 9. List of Global Tier 1 Influenzavirus B Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Influenzavirus B Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 15. By Type - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 16. By Application – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 20. By Application - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 21. By Region – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 25. By Region - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 26. By Country - North America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 46. AbbVie Inc Corporate Summary
Table 47. AbbVie Inc Influenzavirus B Infection Drug Product Offerings
Table 48. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Adimmune Corp Corporate Summary
Table 50. Adimmune Corp Influenzavirus B Infection Drug Product Offerings
Table 51. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Altravax Inc Corporate Summary
Table 53. Altravax Inc Influenzavirus B Infection Drug Product Offerings
Table 54. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. Amarillo Biosciences Inc Corporate Summary
Table 56. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Offerings
Table 57. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Aphios Corp Corporate Summary
Table 59. Aphios Corp Influenzavirus B Infection Drug Product Offerings
Table 60. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. BioCryst Pharmaceuticals Inc Corporate Summary
Table 62. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Offerings
Table 63. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Cadila Healthcare Ltd Corporate Summary
Table 65. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Offerings
Table 66. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. ContraFect Corp Corporate Summary
Table 68. ContraFect Corp Influenzavirus B Infection Drug Product Offerings
Table 69. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Daiichi Sankyo Company Ltd Corporate Summary
Table 71. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Offerings
Table 72. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Fujifilm Holdings Corporation Corporate Summary
Table 74. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Offerings
Table 75. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. GlaxoSmithKline Plc Corporate Summary
Table 77. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Offerings
Table 78. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Green Cross Corp Corporate Summary
Table 80. Green Cross Corp Influenzavirus B Infection Drug Product Offerings
Table 81. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Inovio Pharmaceuticals Inc Corporate Summary
Table 83. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Offerings
Table 84. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Kineta Inc Corporate Summary
Table 86. Kineta Inc Influenzavirus B Infection Drug Product Offerings
Table 87. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Medicago Inc Corporate Summary
Table 89. Medicago Inc Influenzavirus B Infection Drug Product Offerings
Table 90. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. MedImmune LLC Corporate Summary
Table 92. MedImmune LLC Influenzavirus B Infection Drug Product Offerings
Table 93. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Mucosis BV Corporate Summary
Table 95. Mucosis BV Influenzavirus B Infection Drug Product Offerings
Table 96. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 97. Novavax Inc Corporate Summary
Table 98. Novavax Inc Influenzavirus B Infection Drug Product Offerings
Table 99. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 100. Park Active Molecules Corporate Summary
Table 101. Park Active Molecules Influenzavirus B Infection Drug Product Offerings
Table 102. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 103. Romark Laboratories LC Corporate Summary
Table 104. Romark Laboratories LC Influenzavirus B Infection Drug Product Offerings
Table 105. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 106. Sanofi Corporate Summary
Table 107. Sanofi Influenzavirus B Infection Drug Product Offerings
Table 108. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 109. Sanofi Pasteur SA Corporate Summary
Table 110. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Offerings
Table 111. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 112. Shionogi & Co Ltd Corporate Summary
Table 113. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Offerings
Table 114. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 115. SK Chemicals Co Ltd Corporate Summary
Table 116. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Offerings
Table 117. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 118. TSRL Inc Corporate Summary
Table 119. TSRL Inc Influenzavirus B Infection Drug Product Offerings
Table 120. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 121. Vaxart Inc Corporate Summary
Table 122. Vaxart Inc Influenzavirus B Infection Drug Product Offerings
Table 123. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 124. Vectura Group Plc Corporate Summary
Table 125. Vectura Group Plc Influenzavirus B Infection Drug Product Offerings
Table 126. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 127. Influenzavirus B Infection Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 128. Global Influenzavirus B Infection Drug Capacity Market Share of Key Manufacturers, 2020-2022
Table 129. Global Influenzavirus B Infection Drug Production by Region, 2017-2022 (K Pcs)
Table 130. Global Influenzavirus B Infection Drug Production by Region, 2023-2028 (K Pcs)
Table 131. Influenzavirus B Infection Drug Market Opportunities & Trends in Global Market
Table 132. Influenzavirus B Infection Drug Market Drivers in Global Market
Table 133. Influenzavirus B Infection Drug Market Restraints in Global Market
Table 134. Influenzavirus B Infection Drug Raw Materials
Table 135. Influenzavirus B Infection Drug Raw Materials Suppliers in Global Market
Table 136. Typical Influenzavirus B Infection Drug Downstream
Table 137. Influenzavirus B Infection Drug Downstream Clients in Global Market
Table 138. Influenzavirus B Infection Drug Distributors and Sales Agents in Global Market
Table 1. Key Players of Influenzavirus B Infection Drug in Global Market
Table 2. Top Influenzavirus B Infection Drug Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Influenzavirus B Infection Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Influenzavirus B Infection Drug Revenue Share by Companies, 2017-2022
Table 5. Global Influenzavirus B Infection Drug Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Influenzavirus B Infection Drug Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Influenzavirus B Infection Drug Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Influenzavirus B Infection Drug Product Type
Table 9. List of Global Tier 1 Influenzavirus B Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Influenzavirus B Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 15. By Type - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 16. By Application – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 20. By Application - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 21. By Region – Global Influenzavirus B Infection Drug Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Influenzavirus B Infection Drug Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Influenzavirus B Infection Drug Sales (K Pcs), 2017-2022
Table 25. By Region - Global Influenzavirus B Infection Drug Sales (K Pcs), 2023-2028
Table 26. By Country - North America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales, (K Pcs), 2023-2028
Table 46. AbbVie Inc Corporate Summary
Table 47. AbbVie Inc Influenzavirus B Infection Drug Product Offerings
Table 48. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Adimmune Corp Corporate Summary
Table 50. Adimmune Corp Influenzavirus B Infection Drug Product Offerings
Table 51. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Altravax Inc Corporate Summary
Table 53. Altravax Inc Influenzavirus B Infection Drug Product Offerings
Table 54. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. Amarillo Biosciences Inc Corporate Summary
Table 56. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Offerings
Table 57. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Aphios Corp Corporate Summary
Table 59. Aphios Corp Influenzavirus B Infection Drug Product Offerings
Table 60. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. BioCryst Pharmaceuticals Inc Corporate Summary
Table 62. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Offerings
Table 63. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Cadila Healthcare Ltd Corporate Summary
Table 65. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Offerings
Table 66. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. ContraFect Corp Corporate Summary
Table 68. ContraFect Corp Influenzavirus B Infection Drug Product Offerings
Table 69. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Daiichi Sankyo Company Ltd Corporate Summary
Table 71. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Offerings
Table 72. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Fujifilm Holdings Corporation Corporate Summary
Table 74. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Offerings
Table 75. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. GlaxoSmithKline Plc Corporate Summary
Table 77. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Offerings
Table 78. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Green Cross Corp Corporate Summary
Table 80. Green Cross Corp Influenzavirus B Infection Drug Product Offerings
Table 81. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Inovio Pharmaceuticals Inc Corporate Summary
Table 83. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Offerings
Table 84. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Kineta Inc Corporate Summary
Table 86. Kineta Inc Influenzavirus B Infection Drug Product Offerings
Table 87. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Medicago Inc Corporate Summary
Table 89. Medicago Inc Influenzavirus B Infection Drug Product Offerings
Table 90. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. MedImmune LLC Corporate Summary
Table 92. MedImmune LLC Influenzavirus B Infection Drug Product Offerings
Table 93. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Mucosis BV Corporate Summary
Table 95. Mucosis BV Influenzavirus B Infection Drug Product Offerings
Table 96. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 97. Novavax Inc Corporate Summary
Table 98. Novavax Inc Influenzavirus B Infection Drug Product Offerings
Table 99. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 100. Park Active Molecules Corporate Summary
Table 101. Park Active Molecules Influenzavirus B Infection Drug Product Offerings
Table 102. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 103. Romark Laboratories LC Corporate Summary
Table 104. Romark Laboratories LC Influenzavirus B Infection Drug Product Offerings
Table 105. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 106. Sanofi Corporate Summary
Table 107. Sanofi Influenzavirus B Infection Drug Product Offerings
Table 108. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 109. Sanofi Pasteur SA Corporate Summary
Table 110. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Offerings
Table 111. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 112. Shionogi & Co Ltd Corporate Summary
Table 113. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Offerings
Table 114. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 115. SK Chemicals Co Ltd Corporate Summary
Table 116. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Offerings
Table 117. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 118. TSRL Inc Corporate Summary
Table 119. TSRL Inc Influenzavirus B Infection Drug Product Offerings
Table 120. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 121. Vaxart Inc Corporate Summary
Table 122. Vaxart Inc Influenzavirus B Infection Drug Product Offerings
Table 123. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 124. Vectura Group Plc Corporate Summary
Table 125. Vectura Group Plc Influenzavirus B Infection Drug Product Offerings
Table 126. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 127. Influenzavirus B Infection Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 128. Global Influenzavirus B Infection Drug Capacity Market Share of Key Manufacturers, 2020-2022
Table 129. Global Influenzavirus B Infection Drug Production by Region, 2017-2022 (K Pcs)
Table 130. Global Influenzavirus B Infection Drug Production by Region, 2023-2028 (K Pcs)
Table 131. Influenzavirus B Infection Drug Market Opportunities & Trends in Global Market
Table 132. Influenzavirus B Infection Drug Market Drivers in Global Market
Table 133. Influenzavirus B Infection Drug Market Restraints in Global Market
Table 134. Influenzavirus B Infection Drug Raw Materials
Table 135. Influenzavirus B Infection Drug Raw Materials Suppliers in Global Market
Table 136. Typical Influenzavirus B Infection Drug Downstream
Table 137. Influenzavirus B Infection Drug Downstream Clients in Global Market
Table 138. Influenzavirus B Infection Drug Distributors and Sales Agents in Global Market
LIST OF FIGURES
Figure 1. Influenzavirus B Infection Drug Segment by Type
Figure 2. Influenzavirus B Infection Drug Segment by Application
Figure 3. Global Influenzavirus B Infection Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Influenzavirus B Infection Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Influenzavirus B Infection Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. Influenzavirus B Infection Drug Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2021
Figure 9. By Type - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 10. By Type - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 11. By Type - Global Influenzavirus B Infection Drug Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 13. By Application - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 14. By Application - Global Influenzavirus B Infection Drug Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 16. By Region - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 17. By Country - North America Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 18. By Country - North America Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 19. US Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 24. Germany Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 25. France Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 33. China Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 37. India Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 39. By Country - South America Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 40. Brazil Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 44. Turkey Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 48. Global Influenzavirus B Infection Drug Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Influenzavirus B Infection Drug by Region, 2021 VS 2028
Figure 50. Influenzavirus B Infection Drug Industry Value Chain
Figure 51. Marketing Channels
Figure 1. Influenzavirus B Infection Drug Segment by Type
Figure 2. Influenzavirus B Infection Drug Segment by Application
Figure 3. Global Influenzavirus B Infection Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Influenzavirus B Infection Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Influenzavirus B Infection Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. Influenzavirus B Infection Drug Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2021
Figure 9. By Type - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 10. By Type - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 11. By Type - Global Influenzavirus B Infection Drug Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 13. By Application - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 14. By Application - Global Influenzavirus B Infection Drug Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 16. By Region - Global Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 17. By Country - North America Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 18. By Country - North America Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 19. US Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 24. Germany Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 25. France Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 33. China Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 37. India Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 39. By Country - South America Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 40. Brazil Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Influenzavirus B Infection Drug Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Influenzavirus B Infection Drug Sales Market Share, 2017-2028
Figure 44. Turkey Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Influenzavirus B Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 48. Global Influenzavirus B Infection Drug Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Influenzavirus B Infection Drug by Region, 2021 VS 2028
Figure 50. Influenzavirus B Infection Drug Industry Value Chain
Figure 51. Marketing Channels
